Pharmacokinetic - pharmacodynamic analysis of the arrhythmogenic potency of a novel antiallergic agent, ebastine, in rats

Hisakazu Ohtani, Hitoshi Sato, Tatsuji Iga, Hajime Kotaki, Yasufumi Sawada

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Ebastine (EBS), a novel nonsedative antiallergic agent, is similar to terfenadine in its chemical structure. However, clinical arrhythmogenicity of EBS remains controversial. In this study, we evaluated the possible arrhythmogenic potency of EBS as assessed by QT prolongation from a pharmacokinetic-pharmacodynamic viewpoint in comparison with that of terfenadine. EBS was intravenously infused into anesthetized rats at a rate of 3.0 or 10 mg/kg/h for 60 min, and electrocardiographic effects were continuously monitored from lead II. The plasma concentrations of EBS and its major metabolite, carebastine, were also measured under the same conditions. When intravenously administered, EBS exhibited QT prolongation in an infusion rate-dependent manner, with a lag time. Pharmacokinetic-pharmacodynamic analysis of EBS based on the effect-compartment model revealed values of EC50, E(max) and EC10 (ms) (where 10 ms of QT prolongation was evoked) of 0.73 μg/ml, 12.5 ms and 2.90 μg/mL, respectively. The EC(10 ms) value of EBS was five times higher than that of terfenadine reported previously In conclusion, EBS was suggested to be less arrhythmogenic than terfenadine.

Original languageEnglish
Pages (from-to)101-106
Number of pages6
JournalBiopharmaceutics and Drug Disposition
Volume20
Issue number2
DOIs
Publication statusPublished - 1999
Externally publishedYes

Fingerprint

Anti-Allergic Agents
Pharmacokinetics
Terfenadine
ebastine

Keywords

  • Arrhythmia
  • Ebastine
  • ECG
  • Pharmacodynamics
  • Terfenadine

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Pharmacokinetic - pharmacodynamic analysis of the arrhythmogenic potency of a novel antiallergic agent, ebastine, in rats. / Ohtani, Hisakazu; Sato, Hitoshi; Iga, Tatsuji; Kotaki, Hajime; Sawada, Yasufumi.

In: Biopharmaceutics and Drug Disposition, Vol. 20, No. 2, 1999, p. 101-106.

Research output: Contribution to journalArticle

@article{a6343b350e244ee4adbaec994ed3bafa,
title = "Pharmacokinetic - pharmacodynamic analysis of the arrhythmogenic potency of a novel antiallergic agent, ebastine, in rats",
abstract = "Ebastine (EBS), a novel nonsedative antiallergic agent, is similar to terfenadine in its chemical structure. However, clinical arrhythmogenicity of EBS remains controversial. In this study, we evaluated the possible arrhythmogenic potency of EBS as assessed by QT prolongation from a pharmacokinetic-pharmacodynamic viewpoint in comparison with that of terfenadine. EBS was intravenously infused into anesthetized rats at a rate of 3.0 or 10 mg/kg/h for 60 min, and electrocardiographic effects were continuously monitored from lead II. The plasma concentrations of EBS and its major metabolite, carebastine, were also measured under the same conditions. When intravenously administered, EBS exhibited QT prolongation in an infusion rate-dependent manner, with a lag time. Pharmacokinetic-pharmacodynamic analysis of EBS based on the effect-compartment model revealed values of EC50, E(max) and EC10 (ms) (where 10 ms of QT prolongation was evoked) of 0.73 μg/ml, 12.5 ms and 2.90 μg/mL, respectively. The EC(10 ms) value of EBS was five times higher than that of terfenadine reported previously In conclusion, EBS was suggested to be less arrhythmogenic than terfenadine.",
keywords = "Arrhythmia, Ebastine, ECG, Pharmacodynamics, Terfenadine",
author = "Hisakazu Ohtani and Hitoshi Sato and Tatsuji Iga and Hajime Kotaki and Yasufumi Sawada",
year = "1999",
doi = "10.1002/(SICI)1099-081X(199903)20:2<101::AID-BDD160>3.0.CO;2-L",
language = "English",
volume = "20",
pages = "101--106",
journal = "Biopharmaceutics and Drug Disposition",
issn = "0142-2782",
publisher = "John Wiley and Sons Ltd",
number = "2",

}

TY - JOUR

T1 - Pharmacokinetic - pharmacodynamic analysis of the arrhythmogenic potency of a novel antiallergic agent, ebastine, in rats

AU - Ohtani, Hisakazu

AU - Sato, Hitoshi

AU - Iga, Tatsuji

AU - Kotaki, Hajime

AU - Sawada, Yasufumi

PY - 1999

Y1 - 1999

N2 - Ebastine (EBS), a novel nonsedative antiallergic agent, is similar to terfenadine in its chemical structure. However, clinical arrhythmogenicity of EBS remains controversial. In this study, we evaluated the possible arrhythmogenic potency of EBS as assessed by QT prolongation from a pharmacokinetic-pharmacodynamic viewpoint in comparison with that of terfenadine. EBS was intravenously infused into anesthetized rats at a rate of 3.0 or 10 mg/kg/h for 60 min, and electrocardiographic effects were continuously monitored from lead II. The plasma concentrations of EBS and its major metabolite, carebastine, were also measured under the same conditions. When intravenously administered, EBS exhibited QT prolongation in an infusion rate-dependent manner, with a lag time. Pharmacokinetic-pharmacodynamic analysis of EBS based on the effect-compartment model revealed values of EC50, E(max) and EC10 (ms) (where 10 ms of QT prolongation was evoked) of 0.73 μg/ml, 12.5 ms and 2.90 μg/mL, respectively. The EC(10 ms) value of EBS was five times higher than that of terfenadine reported previously In conclusion, EBS was suggested to be less arrhythmogenic than terfenadine.

AB - Ebastine (EBS), a novel nonsedative antiallergic agent, is similar to terfenadine in its chemical structure. However, clinical arrhythmogenicity of EBS remains controversial. In this study, we evaluated the possible arrhythmogenic potency of EBS as assessed by QT prolongation from a pharmacokinetic-pharmacodynamic viewpoint in comparison with that of terfenadine. EBS was intravenously infused into anesthetized rats at a rate of 3.0 or 10 mg/kg/h for 60 min, and electrocardiographic effects were continuously monitored from lead II. The plasma concentrations of EBS and its major metabolite, carebastine, were also measured under the same conditions. When intravenously administered, EBS exhibited QT prolongation in an infusion rate-dependent manner, with a lag time. Pharmacokinetic-pharmacodynamic analysis of EBS based on the effect-compartment model revealed values of EC50, E(max) and EC10 (ms) (where 10 ms of QT prolongation was evoked) of 0.73 μg/ml, 12.5 ms and 2.90 μg/mL, respectively. The EC(10 ms) value of EBS was five times higher than that of terfenadine reported previously In conclusion, EBS was suggested to be less arrhythmogenic than terfenadine.

KW - Arrhythmia

KW - Ebastine

KW - ECG

KW - Pharmacodynamics

KW - Terfenadine

UR - http://www.scopus.com/inward/record.url?scp=0033003121&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033003121&partnerID=8YFLogxK

U2 - 10.1002/(SICI)1099-081X(199903)20:2<101::AID-BDD160>3.0.CO;2-L

DO - 10.1002/(SICI)1099-081X(199903)20:2<101::AID-BDD160>3.0.CO;2-L

M3 - Article

VL - 20

SP - 101

EP - 106

JO - Biopharmaceutics and Drug Disposition

JF - Biopharmaceutics and Drug Disposition

SN - 0142-2782

IS - 2

ER -